DALLAS and NEW HAVEN, Conn., Jan. 14 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) and RHEI Pharmaceuticals, Inc. ("RHEI"), a specialty pharmaceutical company focused on bringing proprietary medicines to the China market, today announced the signing of a definitive licensing agreement under which RHEI, which has more than 110 national sales representatives penetrating large volume hospitals, will market Access's proprietary product MuGard(TM) in the Peoples Republic of China and certain other Southeast Asian countries. MuGard(TM) has received marketing allowance from the U.S. Food and Drug Administration for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Oral mucositis has become a significant unmet medical need as a result of improved medical care in China and the Southeast Asian region. RHEI will be responsible for marketing MuGard in the People's Republic of China, Hong Kong, Macau, Taiwan, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand and Vietnam, as well as for manufacturing and for obtaining the necessary regulatory approvals for the product in the territory.
"We are pleased to have MuGard in our portfolio of products in China, building on our expertise in the area of oncology," said Dr. X. Sylvia He, Chief Executive Officer of RHEI. "Our mission is to bring innovative products to the Chinese market and MuGard fulfills a real medical need. With an increasing number of patients receiving radiation and chemotherapy in China, the prevalence of oral mucositis is growing. Our expert capabilities in sales and marketing, manufacturing and regulatory will help to maximize MuGard's potential in the marketplace."
"RHEI is a great partner for us in China," added Jeffrey B. Davis,
Chief Executive Officer of Access. "We are excited about the potential for
MuGard in China and believe RHEI is uniquely positioned to commercialize
|SOURCE Access Pharmaceuticals, Inc.; RHEI Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved